Noam Solomon (L) and Luis Voloch, Immunai co-founders
October 27, 2021 01:15 PM EDT
Financing
AI

Koch leads mam­moth $215M in­fu­sion in­to AI start­up boast­ing 'largest data­base' of im­mune cells

Amber Tong

In the three years since Noam Solomon and Luis Voloch start­ed Im­mu­nai, the com­pa­ny has quick­ly out­grown its digs.

Im­mu­nai’s team went from 30 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times